Your browser doesn't support javascript.
loading
[Anticipating Criteria for Discharge after Lu-177-PSMA Treatment - Discussion of Several Scenarios]. / Vorausschauende Entlassungskriterien nach Lu-177-PSMA-Therapie ­ Diskussion unterschiedlicher Szenarien.
Kranert, Wolfgang Tilman; Bockisch, Benjamin; Wichert, Jennifer; Gröner, Daniel; Sabet, Amir; Baumgarten, Justus; Nguyen Ngoc, Linh Quyen Christina; Grünwald, Frank; Happel, Christian.
Affiliation
  • Kranert WT; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Bockisch B; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Wichert J; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Gröner D; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Sabet A; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Baumgarten J; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Nguyen Ngoc LQC; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Grünwald F; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
  • Happel C; University Hospital, Department of Nuclear Medicine, Goethe University Frankfurt, Frankfurt am Main, Germany.
Nuklearmedizin ; 61(2): 111-119, 2022 Apr.
Article in De | MEDLINE | ID: mdl-35170005
ABSTRACT

AIM:

The aim is to add a pragmatic contribution to the discussion of an algorithm to discharge patients treated with Lu-177-PSMA under the aspect of radiation protection. This also may be applied to therapies with other radioactive tracers in the future. MATERIAL AND

METHODS:

478 cycles of Lu-177-PSMA-617 (140 patients) were analyzed. The remaining activity in the patient and the dose rate were correlated. From frequent intratherapeutic measurements (biexponential fit) scenarios for discharging patients are deduced.

RESULTS:

Thirty-four per cent of all patients treated with Lu-177-PSMA received 3 to 5 cycles per calendar year. The dose limit of 1 mSv per calendar year (German Law) at a distance of 2 m from the patient would be exceeded in 10 % and 15 % of the treated patients if discharged 72 hours after treatment given 3 and 4 cycles per calendar year, respectively. Mean specific dose rate was 0.00462µSv/(h MBq) at a distance of 1 m. A universal correlation between dose rate and the remaining activity in the patient could not be found.

CONCLUSION:

The multi cycle concept of the therapies with Lu-177 PSMA has to be taken into account prospectively when discharging the patients. Given the physical half-life of Lu-177 an anticipation of 4 treatment cycles per calendar year leads to a clearly arranged, conservative rule.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Lutetium Limits: Humans / Male Language: De Journal: Nuklearmedizin Year: 2022 Document type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms, Castration-Resistant / Lutetium Limits: Humans / Male Language: De Journal: Nuklearmedizin Year: 2022 Document type: Article Affiliation country: Germany